We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
Read MoreHide Full Article
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp recently entered into a multi-faceted collaboration agreement to expand clinical trial access in New Jersey. The company joined forces with Circuit Clinical, a physicians and clinical research professionals network, and Riverside Medical Group (RMG), a NJ-based regional medical practice.
Financial terms of the deal have been kept under wraps.
Deal Details
Per the agreement, RMG's patients will be able to participate in clinical trials of new treatments and therapies within their own doctor's office. RMG has opened a dedicated research site jointly operated with Circuit Clinical. LabCorp, which is the primary reference laboratory for RMG, will help identify clinical trials for which RMG patients are eligible.
Precisely, all the three entities will jointly work for fast enrollment of patients in the trials being managed by LabCorp's Covance drug development business unit. Covance conducts clinical trials for biopharmaceutical and medical device companies. This in a way is expected to help accelerate the development of new medicines in multiple areas, including oncology and many other acute and chronic conditions.
Deal Benefits for LabCorp
The collaboration with RMG, which is a leading medical practice in New Jersey, with 96 locations that service more than 350,000 patients annually, is expected to broaden LabCorp’s existing client network to a significant extent. LabCorp’s Patient Direct offering will be used, which will help in bringing suitable clinical trials to eligible patients directly.
Covance Updates
This business has been benefiting from collaborations on potential antivirals, treatments and vaccines with leading pharmaceutical and biotechnology companies. Of late, LabCorp is enhancing Covance's offerings through strategic acquisitions. The acquisition of MI Bioresearch is expected to create an opportunity for Covance to move from preclinical to clinical development. We are also optimistic about the company’s plans to acquire Regulatory and Clinical Research Institute (RCRI), a device-focused Contract Research Organization (CRO) with strong regulatory consulting expertise.
In terms of COVID-19 related support, among Covance’s collaborations, the alliance with Ridgeback Biotherapeutics to test an antiviral drug is significant. Further, the Covance business is also working with companies like Adaptive Biotechnologies and Microsoft to focus on immune response to the coronavirus. Separately, it is also working with Pacific Bioscience on unique research programs on virus characteristics that can support patient treatment decisions. Meanwhile, the company launched its patient registry which Ciox Health that will enable researchers to better understand and characterize COVID-19 diagnosis and treatment and generate the insights that will aid ongoing and future pandemic preparedness and prevention efforts.
Price Performance
Shares of the company have gained 13.2% in the past year compared with the industry’s rise of 9.7%.
Zacks Rank & Other Key Picks
Currently, LabCorp sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.
Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Shutterstock
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp recently entered into a multi-faceted collaboration agreement to expand clinical trial access in New Jersey. The company joined forces with Circuit Clinical, a physicians and clinical research professionals network, and Riverside Medical Group (RMG), a NJ-based regional medical practice.
Financial terms of the deal have been kept under wraps.
Deal Details
Per the agreement, RMG's patients will be able to participate in clinical trials of new treatments and therapies within their own doctor's office. RMG has opened a dedicated research site jointly operated with Circuit Clinical. LabCorp, which is the primary reference laboratory for RMG, will help identify clinical trials for which RMG patients are eligible.
Precisely, all the three entities will jointly work for fast enrollment of patients in the trials being managed by LabCorp's Covance drug development business unit. Covance conducts clinical trials for biopharmaceutical and medical device companies. This in a way is expected to help accelerate the development of new medicines in multiple areas, including oncology and many other acute and chronic conditions.
Deal Benefits for LabCorp
The collaboration with RMG, which is a leading medical practice in New Jersey, with 96 locations that service more than 350,000 patients annually, is expected to broaden LabCorp’s existing client network to a significant extent. LabCorp’s Patient Direct offering will be used, which will help in bringing suitable clinical trials to eligible patients directly.
Covance Updates
This business has been benefiting from collaborations on potential antivirals, treatments and vaccines with leading pharmaceutical and biotechnology companies. Of late, LabCorp is enhancing Covance's offerings through strategic acquisitions. The acquisition of MI Bioresearch is expected to create an opportunity for Covance to move from preclinical to clinical development. We are also optimistic about the company’s plans to acquire Regulatory and Clinical Research Institute (RCRI), a device-focused Contract Research Organization (CRO) with strong regulatory consulting expertise.
In terms of COVID-19 related support, among Covance’s collaborations, the alliance with Ridgeback Biotherapeutics to test an antiviral drug is significant. Further, the Covance business is also working with companies like Adaptive Biotechnologies and Microsoft to focus on immune response to the coronavirus. Separately, it is also working with Pacific Bioscience on unique research programs on virus characteristics that can support patient treatment decisions. Meanwhile, the company launched its patient registry which Ciox Health that will enable researchers to better understand and characterize COVID-19 diagnosis and treatment and generate the insights that will aid ongoing and future pandemic preparedness and prevention efforts.
Price Performance
Shares of the company have gained 13.2% in the past year compared with the industry’s rise of 9.7%.
Zacks Rank & Other Key Picks
Currently, LabCorp sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.
Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>